Table 3

Subgroup analysis

SubgroupOutcome measureAnalysisDonepezilPlaceboTreatment effect*P values
Means (errors)Means (errors)Means(95%CI)
e4 (−)Psychosis development
  HR for psychosis in 48 weeksCox0.31(0.11 to 0.86)0.02
  HR for psychosis in 96 weeksCox0.63(0.28 to 1.41)0.26
  Cx in total PPQGEE−0.28 (0.167)0.60 (0.209)−0.88(−1.41 to −0.36)0.001
Sleepiness
  Cx in ESSGEE0.45 (1.93)1.85 (1.93)−1.4(−2.65 to −0.16)0.027
e4 (+)Psychosis development
  HR for psychosis in 48 weeksCox0.85(0.19 to 3.79)0.84
  HR for psychosis in 96 weeksCox0.86(0.23 to 3.32)0.83
  Cx in total PPQGEE0.02 (0.30)0.20 (0.331)−0.18(−1.05 to 0.70)0.69
Sleepiness
  Cx in ESSGEE1.26 (3.13)0.51 (3.19)0.75(−0.85 to 2.35)0.36
  • *Effect size was estimated using GEE (working matrix M-dependent), adjusted for ESS/10, mH-Y (2.5 vs 3–4) and psychosis history.

  • Cx, changes; ESS, Epworth Sleep Scale; GEE, generalised estimating equation; mH-Y, modified Hoehn-Yahr; PPQ, Parkinson’s Psychosis Questionnaire.